{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:38:34Z","timestamp":1792013914960,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,8,12]],"date-time":"2019-08-12T00:00:00Z","timestamp":1565568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Oral ulcers, the hallmark lesion of Beh\u00e7et's disease (<jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>), can be disabling and resistant to conventional treatment, and there is a need for safe and effective treatment. We undertook this study to investigate the long\u2010term safety and efficacy of ustekinumab therapy for <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>\u2010related oral ulcers that are resistant to colchicine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicenter, prospective, open\u2010label study included 30 patients who fulfilled the criteria of the International Study Group for <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> and who were diagnosed as having active oral ulcers resistant to colchicine. Patients were treated subcutaneously with ustekinumab 90 mg at inclusion, at week 4, and then once every 12 weeks. Each patient was assessed longitudinally for the presence and number of oral ulcers, and median numbers of oral ulcers (with interquartile range [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>]) were calculated. The primary efficacy end point was the proportion of patients at week 12 who experienced complete response, defined as having no oral ulcers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median number of oral ulcers per patient during ustekinumab therapy was significantly lower at week 12 compared to baseline (0 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 0\u20131] versus 2 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 2\u20133]; <jats:italic>P<\/jats:italic> &lt; 0.0001). Complete response was achieved in 60.0% and 88.9% of patients at weeks 12 and 24, respectively. The median Beh\u00e7et's Syndrome Activity Score (in which higher scores indicate more active disease) was significantly lower at weeks 12 and 24 (17.5 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 10\u201342.5] and 10 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 8\u201311], respectively) versus baseline (70 [<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 50\u201370]; <jats:italic>P<\/jats:italic> &lt; 0.0001). After a median follow\u2010up of 12 months (<jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content> 6\u201316 months), 26 patients (86.7%) were still receiving ustekinumab treatment. Reasons for ustekinumab discontinuation included <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content> flare (n = 3) and side effects (n = 1). Seven patients (23.3%) experienced adverse events, including headaches (n = 4) and asthenia (n = 2), with no serious side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Ustekinumab seems to be effective in treating <jats:styled-content style=\"fixed-case\">BD<\/jats:styled-content>\u2010related oral ulcers that are resistant to treatment with colchicine.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.40912","type":"journal-article","created":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T07:13:48Z","timestamp":1555917228000},"page":"1727-1732","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Long\u2010Term Outcome of Ustekinumab Therapy for Beh\u00e7et's Disease"],"prefix":"10.1002","volume":"71","author":[{"given":"Adrien","family":"Mirouse","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9 Centre National de R\u00e9f\u00e9rence Maladies Auoimmunes Syst\u00e9miques Rares Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire INSERM 959, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Barete","sequence":"additional","affiliation":[{"name":"Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP, and D\u00e9partement Hospitalo\u2010Universitaire Inflammation\u2010Immunopathologie\u2010Biotherapie  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Claire","family":"Desbois","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 Centre National de R\u00e9f\u00e9rence Maladies Auoimmunes Syst\u00e9miques Rares Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire INSERM 959, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clo\u00e9","family":"Comarmond","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 Centre National de R\u00e9f\u00e9rence Maladies Auoimmunes Syst\u00e9miques Rares Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire INSERM 959, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"S\u00e8ne","sequence":"additional","affiliation":[{"name":"H\u00f4pital Lariboisi\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Domont","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 Centre National de R\u00e9f\u00e9rence Maladies Auoimmunes Syst\u00e9miques Rares Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire INSERM 959, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[{"name":"Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Ferfar","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 Centre National de R\u00e9f\u00e9rence Maladies Auoimmunes Syst\u00e9miques Rares Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire INSERM 959, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-4992","authenticated-orcid":false,"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 Centre National de R\u00e9f\u00e9rence Maladies Auoimmunes Syst\u00e9miques Rares Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire INSERM 959, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9 Centre National de R\u00e9f\u00e9rence Maladies Auoimmunes Syst\u00e9miques Rares Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire INSERM 959, Groupe Hospitalier Piti\u00e9\u2010Salp\u00eatri\u00e8re AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the French Beh\u00e7et's Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8,12]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411707"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200101000-00004"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213225"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408684"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2007.06.006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.12.009"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-009-0246-1"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2014.10.008"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.625"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.624"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2017.05.002"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12107"},{"key":"e_1_2_6_14_1","first-page":"77","article-title":"Patient\u2010driven assessment of disease activity in Beh\u00e7et's syndrome: cross\u2010cultural adaptation, reliability and validity of the Turkish version of the Beh\u00e7et's Syndrome Activity Score","volume":"31","author":"Yilmaz S","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.014"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2014.06.005"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.11.1074"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker423"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204741"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202392"},{"key":"e_1_2_6_24_1","first-page":"69","article-title":"Efficacy of ustekinumab against infliximab\u2010induced psoriasis and arthritis associated with Crohn's disease","volume":"12","author":"Matsumoto S","year":"2018","journal-title":"Biologics"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40728"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1086\/511051"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x"},{"issue":"2","key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/annrheumdis-2018-eular.5627","article-title":"OP0082 Apremilast for Beh\u00e7et's syndrome: a phase III randomised, placebo\u2010controlled, double\u2010blind study (RELIEF) [abstract]","volume":"77","author":"Hatemi G","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40912","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.40912","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:18:32Z","timestamp":1759954712000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,12]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1002\/art.40912"],"URL":"https:\/\/doi.org\/10.1002\/art.40912","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,12]]},"assertion":[{"value":"2018-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}